Last updated: February 20, 2026
What Are the Core Patentability Criteria for Biopharmaceuticals in Taiwan?
Taiwan's Intellectual Property Office (TIPO) assesses biopharmaceutical patents using criteria aligned with international standards based on the Patent Act, amended for biotechnological innovations.
Novelty: The invention must be new and not disclosed prior to the filing date. Prior disclosures include publications, public uses, or existing patents in Taiwan or any jurisdiction. Disclosures within 12 months before filing, via grace period, are generally accepted unless they fall under specific exclusions.
Inventiveness (Non-Obviousness): The invention must not be obvious to a person skilled in the relevant field. This assessment factors in existing knowledge, prior art, and the technical problem addressed by the invention.
Industrial Applicability: The invention must have a specific, substantial, and credible utility. The patent office assesses if the biopharmaceutical has clear therapeutic or diagnostic benefits.
Subject Matter Eligibility: Patentable subject matter excludes discoveries without a concrete technical contribution, such as mere discoveries of naturally occurring substances unless involving a technical process or application.
How Is Patent Enforceability Under Taiwan Law?
Enforceability depends on compliance with patent filing, substantive examination, and maintenance procedures.
Examination Process: Taiwan conducts substantive examination for biopharmaceutical patents, focusing on inventive step, clarity of claims, and patentable subject matter. Strong articulation of novelty and inventive step in patent specifications enhances enforceability.
Prior Art and Invalidity Challenges: Patent validity can be challenged via opposition proceedings within nine months after grant or through invalidation actions afterward. Common grounds include lack of novelty, inventive step, or insufficient disclosure.
Patent Term: The term lasts for 20 years from the filing date, subject to fee payment and patent term adjustments, particularly relevant where regulatory delays occur.
Data Exclusivity: Taiwan offers data exclusivity periods for new drugs: six years for chemical drugs and five years for biologics, safeguards that delay generic entry independent of patent rights.
How Do Claims in Taiwan Biopharmaceutical Patents Typically Range?
Patent claims define the scope of protection. Taiwan emphasizes broad claims supported by detailed specifications.
Type of Claims
-
Compound Claims: Cover novel molecules, analogs, or formulations.
-
Use Claims: Cover specific therapeutic, diagnostic, or manufacturing applications.
-
Process Claims: Cover methods of production or formulation.
Claim Scope Considerations
-
Product-by-Process Claims are permissible but limited in scope, especially if based solely on process features.
-
Markush Groups are permitted to encompass multiple embodiments, increasing breadth.
-
Structural versus Functional Claims: Structural claims are generally stronger and easier to enforce. Functional claims must be supported by detailed disclosure to avoid being too vague.
Claim Drafting Strategies
-
Emphasize novelty by including specific chemical structures or unique production steps.
-
Carve out multiple dependent claims narrowing the invention, which can serve as fallback positions during enforcement.
-
Use multiple claim types (composition, use, process) to maximize scope and defend against invalidation.
Key Differences Compared to International Standards
-
Taiwan places emphasis on clear disclosure linking claims to specific technical features.
-
The scope of data exclusivity surpasses patent rights in protecting timely generic entry.
-
Support for broad claims exists but is constrained by strict novelty and inventive step standards, especially for complex biopharmaceuticals.
Practical Implications for Patent Applicants
-
Ensure detailed and specific disclosures, especially regarding biological materials and processes.
-
Anticipate prior art and include multiple claim types to robustly secure patent rights.
-
Monitor patent term adjustments and data exclusivity regimes to optimize market protection.
Key Takeaways
- Taiwan prioritizes novelty and inventive step, especially for complex biopharmaceuticals.
- Patents last for 20 years, supported by thorough examination and clear documentation.
- Broad claims are possible but must be well-supported; use multiple claim types for maximum scope.
- Data exclusivity provides a period of market protection independent of patent rights.
- Enforcement hinges on strong, detailed patent specifications and proactive litigation strategies.
Frequently Asked Questions
1. Can naturally occurring biomolecules be patented in Taiwan?
Generally, no. Naturally occurring substances are excluded unless linked to a technical process or modified to produce a new technical effect.
2. What is Taiwan’s approach to patenting biological processes?
Processes for manufacturing biologics are patentable if they involve inventive steps that produce a new and useful result. Disclosure must be detailed and enable replication.
3. How does Taiwan handle patent opposition for biopharmaceuticals?
Opposition can be filed within nine months of patent grant, focusing on lack of novelty, inventive step, or sufficient disclosure. Invalidity can be challenged in later proceedings.
4. What is the impact of data exclusivity on generic entry?
Data exclusivity prevents generic companies from relying on originator clinical test data for six years for chemical drugs and five years for biologics, delaying market entry despite patent status.
5. Are method-of-use claims effective in Taiwan?
Yes, method-of-use claims are recognized and can be enforceable if supported by sufficient evidence, especially when the use involves specific therapeutic indications not covered by prior art.
References
[1] Taiwan Patent Act (2022). Ministry of Justice.
[2] Taiwan Intellectual Property Office (TIPO). (2020). Guidelines for Patent Examination.
[3] World Intellectual Property Organization. (2021). Patent protection for biotechnological inventions in Asia.
[4] European Patent Office. (2020). Guidance on patenting biological materials and processes.
[5] Kuo, S. (2018). IP laws and biotech innovation: Taiwan case study. Journal of Intellectual Property Law, 25(1), 45-67.
